SCHEMBL1476900

SCHEMBL1476900

N#Cc1cncc(/C=C/c2ccccc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 2/20 0.65
CYP11B1 P15538 1/20 0.48
CYP11B2 P19099 1/20 0.48
PDGFRB P09619 1/20 0.42
PDGFRA P16234 1/20 0.42
PADI4 Q9UM07 1/20 0.42
GRM4 Q14833 1/20 0.41
AKT1 P31749 2/20 0.40
TSHR P16473 1/20 0.40
AURKA O14965 1/20 0.40
KDR P35968 1/20 0.40
PRKCQ Q04759 3/20 0.40
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PRKCD Q05655 1/20 0.39
CHRNB1 P11230 1/20 0.39
CHRNB2 P17787 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1476902 1.00 RAF1 (0.65) RAF1CYP11B1CYP11B2PDGFRBPDGFRA
SCHEMBL1477006 0.88 RAF1 (0.68) RAF1AKT1
SCHEMBL1477004 0.88 RAF1 (0.68) RAF1AKT1
SCHEMBL1478735 0.83 RAF1 (0.57) RAF1CYP11B1CYP11B2AKT1AURKA
SCHEMBL1476571 0.83 RAF1 (0.57) RAF1CYP11B1CYP11B2PADI4AURKA
SCHEMBL1476572 0.83 RAF1 (0.57) RAF1CYP11B1CYP11B2PADI4AURKA
SCHEMBL1478736 0.83 RAF1 (0.57) RAF1CYP11B1CYP11B2AKT1AURKA
SCHEMBL1476920 0.82 RAF1 (0.61) RAF1AKT1AURKAKDRALDH1A1
SCHEMBL1477163 0.82 RAF1 (0.61) RAF1MEN1KMT2A
SCHEMBL1476922 0.82 RAF1 (0.61) RAF1AKT1AURKAKDRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915424-B2 Analgesics; anxiolytic agents ELI LILLY AND COMPANY (US) 2011-03-29 US disclosed
EP-1729771-B1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-14 EP disclosed
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists ELI LILLY AND COMPANY (US) 2008-08-14 US disclosed
EP-1729771-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS Eli Lilly & Company (US) 2006-12-13 EP disclosed
WO-2005094822-A1 PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194647-A1 Pyridyl Derivatives and Their Use as Mglu5 Antagonists HRH4, CNR2, CNR1 RAF1 4597/4885CYP11B1 1606/4885CYP11B2 1328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.